apo-azelastine/fluticasone spray, metered dose
apotex inc - fluticasone propionate; azelastine hydrochloride - spray, metered dose - 50mcg; 137mcg - fluticasone propionate 50mcg; azelastine hydrochloride 137mcg
pms-fluticasone propionate/salmeterol dpi powder
pharmascience inc - fluticasone propionate; salmeterol (salmeterol xinafoate) - powder - 100mcg; 50mcg - fluticasone propionate 100mcg; salmeterol (salmeterol xinafoate) 50mcg - adrenals
pms-fluticasone propionate/salmeterol dpi powder
pharmascience inc - fluticasone propionate; salmeterol (salmeterol xinafoate) - powder - 250mcg; 50mcg - fluticasone propionate 250mcg; salmeterol (salmeterol xinafoate) 50mcg - adrenals
pms-fluticasone propionate/salmeterol dpi powder
pharmascience inc - fluticasone propionate; salmeterol (salmeterol xinafoate) - powder - 500mcg; 50mcg - fluticasone propionate 500mcg; salmeterol (salmeterol xinafoate) 50mcg - adrenals
apo-fluticasone hfa metered-dose aerosol
apotex inc - fluticasone propionate - metered-dose aerosol - 250mcg - fluticasone propionate 250mcg - adrenals
apo-fluticasone hfa metered-dose aerosol
apotex inc - fluticasone propionate - metered-dose aerosol - 125mcg - fluticasone propionate 125mcg
apo-fluticasone hfa aerosol, metered dose
apotex inc - fluticasone propionate - aerosol, metered dose - 50mcg - fluticasone propionate 50mcg
fluticasone salmeterol cip haler 250/50 fluticasone propionate/salmeterol 250/50 mcg/dose inhalation powder pre-dispensed bp plastic inhaler
cipla australia pty ltd - salmeterol xinafoate, quantity: 0.0725 mg; fluticasone propionate, quantity: 0.25 mg - inhalation, powder for - excipient ingredients: lactose monohydrate - for the regular treatment of asthma, where the use of a combination product is appropriate. this may include ? patients on effective maintenance doses of long acting beta 2 agonists and inhaled corticosteroids ? patients who are symptomatic on current inhaled corticosteroid therapy for the symptomatic treatment of patients with severe copd (fev1 not more than 50 per cent predicted normal) and a history of repeated exacerbations who have significant symptoms despite regular beta 2 agonist bronchodilator therapy. fluticasone salmeterol cip haler 250/50 is not indicated for the initiation of bronchodilator therapy in copd.
fluticasone salmeterol multi haler 250/50 fluticasone propionate/salmeterol 250/50 mcg/dose inhalation powder pre-dispensed bp plastic inhaler
cipla australia pty ltd - salmeterol xinafoate, quantity: 0.0725 mg; fluticasone propionate, quantity: 0.25 mg - inhalation, powder for - excipient ingredients: lactose monohydrate - for the regular treatment of asthma, where the use of a combination product is appropriate. this may include ? patients on effective maintenance doses of long acting beta 2 agonists and inhaled corticosteroids ? patients who are symptomatic on current inhaled corticosteroid therapy for the symptomatic treatment of patients with severe copd (fev1 not more than 50 per cent predicted normal) and a history of repeated exacerbations who have significant symptoms despite regular beta 2 agonist bronchodilator therapy. fluticasone salmeterol multi haler 250/50 is not indicated for the initiation of bronchodilator therapy in copd
fluticasone propionate 50 micrograms/actuation, nasal spray, suspension
haleon ireland limited - fluticasone propionate (micronised) - nasal spray, suspension - 50 mcg/acutuation - corticosteroids; fluticasone